Cabotegravir 600 mg / rilpivirine 900 mg Extended Release Kit
RxNorm 2475415

Concept Hierarchy & Relationship Mapping

RxNorm Concept Unique Identifier (RxCUI) 2475415 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: cabotegravir 600 mg / rilpivirine 900 mg Extended Release Kit.

The following semantic concepts and normalized strings are associated with this clinical entity:

PSN
Cabotegravir 600 mg / rilpivirine 900 mg Extended Release Kit
AUI:12535730
View
SY
Cabotegravir 600 mg / rilpivirine 900 mg Extended Release Kit
AUI:12535731
View
GPCK
{1 (3 mL cabotegravir 200 mg/ML Injection) / 1 (3 mL rilpivirine 300 mg/ML Injection) } Pack
AUI:12732199
View

This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.

PSNPrescribable

Prescribable Name (PSN):
Cabotegravir 600 mg / rilpivirine 900 mg Extended Release Kit
(Atom ID: 12535730)

Clinical Status & Identity

Prescribable Status
YES (Active)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
cabotegravir 600 MG / rilpivirine 900 MG Extended Release Kit
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
N
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
2475415
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
12535730
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
PSN
Prescribable Name (Synonym of another TTY, given for clarity and for display purposes in electronic prescribing applications. Only one PSN per concept.)
Source Code
2475415
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
RxNorm Vocabulary (RXNORM)
The official name and abbreviation for the vocabulary source.
Source Version
20AA_260601F
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
RxNorm Customer Service, , U.S. National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, (888) FIND-NLM, , https://support.nlm.nih.gov/support/create-case/, https://www.nlm.nih.gov/research/umls/rxnorm/
Source licensing contact information.
SYPrescribable

Synonym (SY):
Cabotegravir 600 mg / rilpivirine 900 mg Extended Release Kit
(Atom ID: 12535731)

Clinical Status & Identity

Prescribable Status
YES (Active)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
cabotegravir 600 MG / rilpivirine 900 MG Extended Release Kit
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
N
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
2475415
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
12535731
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
SY
Synonym (Synonym of another TTY, given for clarity.)
Source Code
2475415
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
RxNorm Vocabulary (RXNORM)
The official name and abbreviation for the vocabulary source.
Source Version
20AA_260601F
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
RxNorm Customer Service, , U.S. National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, (888) FIND-NLM, , https://support.nlm.nih.gov/support/create-case/, https://www.nlm.nih.gov/research/umls/rxnorm/
Source licensing contact information.
GPCKPrescribable

Generic Pack (GPCK):
{1 (3 mL cabotegravir 200 mg/ML Injection) / 1 (3 mL rilpivirine 300 mg/ML Injection) } Pack
(Atom ID: 12732199)

Clinical Status & Identity

Prescribable Status
YES (Active)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
{1 (3 ML cabotegravir 200 MG/ML Injection) / 1 (3 ML rilpivirine 300 MG/ML Injection) } Pack
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
N
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
2475415
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
12732199
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
GPCK
Generic Pack ({# (Ingredient + Strength + Dose Form) / # (Ingredient + Strength + Dose Form)} Pack)
Source Code
2475415
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
RxNorm Vocabulary (RXNORM)
The official name and abbreviation for the vocabulary source.
Source Version
20AA_260601F
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
RxNorm Customer Service, , U.S. National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, (888) FIND-NLM, , https://support.nlm.nih.gov/support/create-case/, https://www.nlm.nih.gov/research/umls/rxnorm/
Source licensing contact information.

Technical Attributes & Logic

RXN HUMAN DRUG
US
Drug available for use in Humans

Patient Education

Cabotegravir and Rilpivirine Injections


Cabotegravir and rilpivirine injections are used in combination for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in certain adults. Cabotegravir is in a class of medications called HIV integrase inhibitors. Rilpivirine is in a class of medications called non-nucleoside reverse transcriptase inhibitors (NNRTIs). These medications work by decreasing the amount of HIV in the blood. Although cabotegravir and rilpivirine do not cure HIV, they may decrease your chance of developing acquired immunodeficiency syndrome (AIDS) and HIV-related illnesses such as serious infections or cancer. Receiving these medications along with practicing safer sex and making other life-style changes may decrease the risk of transmitting (spreading) the HIV virus to other people.
[Learn More]


* Please review the disclaimer below.